Law firm Kirby McInerney LLP is investigating potential securities fraud claims against Dr. Reddy's Laboratories following the company's disclosure of a ₹2.4 billion provision for out-of-spec semaglutide batches in Q1 FY2027 earnings. The stock fell 9% on the news, though management stated there was no patient safety impact or regulatory filing impact.

The global antiparasitic drugs market is projected to grow from USD 23.30 billion in 2026 to USD 30.98 billion by 2032 at a 4.88% CAGR. Growth is driven by persistent parasitic disease burden, drug resistance, climate-sensitive vector transmission, and public health programs. Key opportunities include resistance-ready combination therapies, pediatric formulations, AI-enabled discovery, and diagnostics-linked prescribing, with Africa and Asia-Pacific leading endemic demand.

The global generic drug market is projected to grow from USD 491.35 billion in 2024 to USD 926.54 billion by 2034, expanding at a CAGR of 6.55%. Growth is driven by increasing demand for cost-effective medicines, rising chronic diseases, and aging populations, particularly in North America and Asia-Pacific regions. However, the market faces challenges from low awareness, branded drug preference among practitioners, and limited rural distribution.

Following the expiration of India's semaglutide patent, over 40 Indian pharmaceutical companies have launched generic versions of Novo Nordisk's Ozempic and Wegovy at dramatically reduced prices—approximately 70% cheaper than originals. Major players like Sun Pharmaceutical, Dr. Reddy's Laboratories, and Zydus Lifesciences are offering monthly treatments ranging from $7.99 to $44.73, with plans to expand into global markets including Canada, Brazil, and Latin America as the obesity market is projected to reach $100 billion by decade's end.

The global tetracyclines market is experiencing steady growth at a CAGR of 5.23%, driven by broad-spectrum efficacy, cost-effectiveness, and expanding applications in respiratory infections, dermatology, and sexual health. Doxycycline dominates with 46.1% market share, while oral formulations lead with 64.0% share. Key growth drivers include rising antibiotic demand in veterinary and aquaculture sectors, emerging clinical applications like Doxy-PEP, and robust supply chains from China and India.

The FDA is considering expediting the review process for Eli Lilly's experimental oral weight-loss treatment, orforglipron, potentially moving the decision date to late March. Rival Novo Nordisk is preparing to launch its own weight-loss pill in December or January.

The Trump administration will exclude imported generic drugs from potential tariffs, bringing relief to pharmaceutical companies and Indian drugmakers who supply nearly half of U.S. generic prescriptions.

Esperion has settled patent litigation with Dr. Reddy's Laboratories, agreeing that generic versions of NEXLETOL and NEXLIZET will not be marketed in the US before April 19, 2040.

Alvotech, a global biotech company specializing in biosimilar medicines, will release its financial results for the first half of 2025 on August 14, 2025, via a webcast and conference call.

The global paracetamol market is projected to grow from USD 876.48 Million in 2024 to USD 1460.23 Million by 2034, with a steady 5.24% CAGR, driven by increasing healthcare awareness and rising incidences of chronic conditions.

Global fibromyalgia treatment market is expanding with novel drug developments, digital health tools, and personalized medicine approaches, driven by increasing awareness and technological innovations in pain management.

A market research study reveals the global Lenacapavir Injection market is expected to grow to USD 5.68 Billion by 2034, with a 5.1% CAGR, driven by long-acting HIV treatment demand and innovations in injectable formulations.